pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
AMGEN · news · pharmadog
← back to AMGEN
News mentioning AMGEN
239
stories
15d
Amgen starts MariTide autoinjector study as pivotal readouts approach
biospace
15d
Minghui grants ASKA Japanese rights to sub-q TED candidate in $440M deal
fiercebiotech
16d
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
fiercebiotech
20d
Assessing Merck and Moderna’s mRNA cancer vaccine
stat
20d
Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
fiercebiotech
21d
8 companies hiring in New York
biospace
22d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
22d
5 new drug launches that defied industry expectations
biospace
23d
A possible treatment for brain-eating amoebas, found in the sea
stat
23d
From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
fiercebiotech
24d
STAT+: Roche gets a lung cancer win with its KRAS drug divarasib
stat
24d
ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
biopharma dive
24d
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
biospace
24d
STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more
stat
25d
#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
endpoints
26d
STAT+: The ESMO presentation everyone’s been waiting for
stat
26d
#ESMO26: Amgen's Imdelltra regimen more than halves risk of death in Phase 3 lung cancer trial
endpoints
26d
ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
fiercebiotech
27d
Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
endpoints
27d
Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra
fiercebiotech
28d
ESMO: Boehringer builds case for late-phase rival to Amgen’s Imdelltra
fiercebiotech
28d
Rebranded NodThera plans IPO to fund NLRP3 inhibitor’s push toward approval
fiercebiotech
28d
ESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps up
fiercebiotech
Oct 19, 26
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
biospace
Oct 19, 26
Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact
fiercebiotech
Oct 14, 26
‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban
biospace
Oct 14, 26
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
Oct 14, 26
Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline
fiercebiotech
Oct 13, 26
Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
biospace
Oct 13, 26
Study pushes for greater adoption of a cloud-based regulatory environment
raps
← prev
page 2 of 8
next →